RETRACTED ARTICLE: CYPA promotes the progression and metastasis of serous ovarian cancer (SOC) in vitro and in vivo

Abstract

Ovarian cancer (OC) is a type of gynaecological malignancy with high mortality in females. Serous ovarian cancer (SOC) is a distinct subtype of OC with poor early diagnosis. Given the limitations of traditional therapies, such as chemotherapy, targeted treatment is therefore a promising therapy to improve the survival rate of SOC patients. Cyclophilin A (CYPA) is a member of Cyclophilin family and thought to participates in multiple cellular processes such as cell transduction and immune modulation. Recently, various of studies indicated that CYPA has critical impact on cancer progression. CYPA could regulate cell proliferation, invasion, and chemoresistance of multiple types of cancers. However, it is still unclear whether it could affect ovarian cancer. In this study, we demonstrated that CYPA was highly expressed in SOC tissues compared with adjacent tissues. Further, CYPA was significantly associated with clinical stage and lymphnode metastasis of SOC patients. Additionally, data indicated that knockdown of CYPA by its shRNA dramatically reduces migration and invasion capacity of SOC cells in vitro and blocks tumor metastasis in vivo. Our study investigates the involvement of CYPA in the progression and metastasis of SOC, and therefore provides CYPA as a promising therapeutic target for SOC treatment.

A Critical Role of Peptidylprolyl Isomerase A Pseudogene 22/microRNA-197-3p/Peptidylprolyl Isomerase A Axis in Hepatocellular Carcinoma

“…Peptidylprolyl isomerase A as one of the most abundant members of cyclophilin (Cyp) family proteins has been reported upregulated in breast cancer ( Volker et al, 2018 ), esophageal cancer ( Qi et al, 2008 ), small cell lung cancer ( Campa et al, 2003 ), colorectal cancer ( Wong et al, 2008 ), pancreatic cancer ( Li et al, 2013 ), melanoma ( Caputo et al, 2011 ), malignant glioblastoma ( Sun et al, 2011 ; Saw et al, 2018 ), serous ovarian cancer ( Qi et al, 2019 ), and skin cancer ( Han et al, 2012 ). Cyps possess a peptidyl prolyl isomerase (PPIase), catalyzing the conversion between cis-trans isomers of proline on the peptide ( Lee, 2013 ).…”

Knockdown of ZNF280A inhibits the development and progression of ovarian cancer

“…Moreover, CDK7 may be a potential therapeutic target for OC patients regardless of platinum sensitivity or drug resistance [24]. Qi et al, found that CYPA is involved in the progression and metastasis of OC, providing a promising therapeutic target for OC therapy [25]. Therefore, targeted therapy shows broad prospects in the treatment of advanced OC.…”

Fabrication of a Novel Au Star@AgAu Yolk-Shell Nanostructure for Ovarian Cancer Early Diagnosis and Targeted Therapy

“…According to previous reports and our research, the concentration of CYPA in patients with early ovarian cancer was significantly increased, compared with healthy women and benign group, and the proportion of CYPA positive reaction was higher in I/II stage. [8][9][10] In addition, the secretion of CYPA in serous ovarian cancer is much higher than that in nearby tissues, and the advanced of ovarian cancer is also closely related to the expression of CYPA. 10 All these indicate that the overexpression of CYPA is intimately associated with the occurrence of ovarian cancer.…”

“…[8][9][10] In addition, the secretion of CYPA in serous ovarian cancer is much higher than that in nearby tissues, and the advanced of ovarian cancer is also closely related to the expression of CYPA. 10 All these indicate that the overexpression of CYPA is intimately associated with the occurrence of ovarian cancer. At present, most of the detection methods of CYPA are chemiluminescence and ELISA, but their detection limit is about 10 −4 -10 −5 µg/mL, which makes its clinical application in early diagnosis of tumors greatly limited.…”